| Literature DB >> 35884899 |
Te-Hsuan Tung1, Yang-Ching Chen1,2,3,4, Ya-Tin Lin2, Shih-Yi Huang1,2,5.
Abstract
The brain-gut-microbiome (BGM) axis affects host bioinformation. N-3 polyunsaturated fatty acids (PUFAs) alleviate cognitive impairment and depression in older adults. This study investigated altered microbiota-bile acid signalling as a potential mechanism linking fish oil-induced gut changes in microbiota to alleviate psychological symptoms. Sprague Dawley rats were fed a fish oil diet and administered D-galactose combined with chronic unpredictable mild stress (CUMS) to simulate geriatric depression. The cognitive function, psychological symptoms, microbiota compositions, and faecal bile acid profiles of the rats were assessed thereafter. A correlation analysis was conducted to determine whether the fish oil-induced alteration of the rats' microbiota and bile acid profiles affected the rats' behaviour. D-galactose and CUMS resulted in lower concentrations of Firmicutes, significantly altered bile acid profiles, and abnormal neurobehaviours. Fish oil intake alleviated the rats' emotional symptoms and increased the abundance of Bacteroidetes, Prevotellaceae, Marinifilaceae, and Bacteroidesuniformis. It also elevated the concentrations of primary bile acids and taurine-conjugated bile acids in the rats' faeces. The rats' taurine-conjugated bile acid levels were significantly correlated with their behavioural outcomes. In short, fish oil intake may alleviate psychological symptoms by altering the microbial metabolites involved in the BGM axis, especially in the conjugation of bile acids.Entities:
Keywords: bile acid; brain−gut−microbiome axis; cognitive impairment; geriatric depression; n-3 polyunsaturated fatty acid
Year: 2022 PMID: 35884899 PMCID: PMC9313093 DOI: 10.3390/biomedicines10071594
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
The composition of diet in different groups.
| Ingredients | Group | ||
|---|---|---|---|
| N, ND, CD, PCD | FCD | CCD | |
| Casein | 140.00 | 140.00 | 140.00 |
| L-Cystine | 1.80 | 1.80 | 1.80 |
| Corn starch | 465.69 | 465.69 | 465.69 |
| Dextrin | 155.00 | 155.00 | 155.00 |
| Sucrose | 100.00 | 100.00 | 100.00 |
| Cellulose | 50.00 | 50.00 | 50.00 |
| Soybean oil | 40.00 | 20.00 | 20.00 |
| Corn oil | 0 | 0 | 20.00 |
| LA | 0 | 0 | 11.2 |
| Fish oil | 0 | 20.00 | 0 |
| Eicosapentaenoic acid (EPA) | 0 | 3.60 | 0 |
| Docosahexaenoic acid (DHA) | 0 | 2.40 | 0 |
| AIN-93M Mineral mix | 35.00 | 35.00 | 35.00 |
| AIN-93M Vitamin mix | 10.00 | 10.00 | 10.00 |
| Choline bitartrate | 2.50 | 2.50 | 2.50 |
| t-butylhydroquinone | 0.01 | 0.01 | 0.01 |
|
| |||
| C14:0 | 1.42 | 5.63 | 1.23 |
| C16:0 | 13.05 | 18.02 | 10.41 |
| C16:1 (n-7) | 0.07 | 0.04 | 0.03 |
| C18:0 | 4.87 | 7.97 | 6.22 |
| C18:1 (n-9) | 17.79 | 9.95 | 19.01 |
| C18:2 (n-6) | 52.71 | 28.74 | 59.52 |
| C18:3 (n-3) | 9.88 | 6.19 | 3.26 |
| C20:1 (n-9) | N.D. | 0.27 | N.D. |
| C20:2 (n-6) | N.D. | 0.38 | N.D. |
| C20:4 (n-6) | 0.01 | 4.08 | 0.01 |
| C20:5 (n-3) | N.D. | 9.63 | N.D. |
| C22:5 (n-3) | 0.18 | 1.46 | 0.08 |
| C22:6 (n-3) | N.D. | 5.98 | N.D. |
| n-6/n-3 ratio | 5.24 | 1.30 | 17.82 |
N: normal control group; ND: D-galactose injection group; CD: CUMS + D-galactose injection group; PCD: CD + imipramine-treated group; FCD: CD + fish oil diet group; CCD: CD + corn oil diet group. Fish oil: containing 30% n-3 PUFAs, EPA:DHA = 3:2.
Figure 1Flow chart of the experiment protocol. Rats were divided into six groups (n = 6). CUMS: chronic unpredictable mild stress; SPT: sucrose preference test; MWM: Morris water maze; FST: forced swimming test.
Effects of fish oil on biochemical parameters in ageing rats.
| Biochemical Characteristics | Group | |||||
|---|---|---|---|---|---|---|
| N | ND | CD | PCD | FCD | CCD | |
| Body weight | 702 ± 48.3 a | 639 ± 73.8 ab | 583 ± 71.3 bc | 522 ± 62.3 c | 585 ± 79.1 bc | 622 ± 56.2 ab |
| FBG (mg/dL) | 99 ± 6 ns | 105 ± 7 | 109 ± 5 | 103 ± 8 | 96 ± 7 | 102 ± 5 |
| ALB (g/dL) | 4.14 ± 0.07 ns | 4.03 ± 0.10 | 4.00 ± 0.08 | 4.13 ± 0.04 | 4.11 ± 0.06 | 4.02 ± 0.09 |
| TG (mg/dL) | 71.3 ± 2.8 a | 80.7 ± 7.3 a | 69.2 ± 5.9 a | 73.9 ± 3.9 a | 60.2 ± 3.6 b | 78.8 ± 5.5 a |
| TC (mg/dL) | 66.6 ± 3.2 b | 70.4 ± 4.3 b | 81.6 ± 5.7 a | 74.5 ± 6.5 b | 68.8 ± 7.1 b | 72.9 ± 10.5 b |
| LDLc (mg/dL) | 6.89 ± 0.91 a | 7.11 ± 0.58 a | 7.94 ± 1.12 a | 5.82 ± 0.55 ab | 5.52 ± 0.31 b | 6.56 ± 0.72 a |
| HDLc (mg/dL) | 23.1 ± 1.4 ns | 24.5 ± 2.2 | 25.0 ± 1.7 | 24.2 ± 1.5 | 19.8 ± 1.8 | 23.6 ± 1.4 |
| AST (U/L) | 87.2 ± 7.2 ns | 76.9 ± 7.1 | 77.4 ± 6.1 | 81.8 ± 5.2 | 79.6 ± 2.9 | 85.2 ± 5.3 |
| BUN (mg/dL) | 20.8 ± 1.6 a | 19.7 ± 1.3 a | 19.9 ± 0.8 a | 16.1 ± 1.0 b | 15.8 ± 1.3 b | 19.1 ± 0.8 a |
| CRE (mg/dL) | 0.60 ± 0.04 b | 0.66 ± 0.06 ab | 0.59 ± 0.05 b | 0.72 ± 0.06 a | 0.68 ± 0.10 a | 0.69 ± 0.06 a |
| TNF-α (pg/mL) | 41.9 ± 3.1 b | 56.3 ± 6.2 a | 69.3 ± 3.7 a | 40.7 ± 5.1 b | 44.3 ± 2.6 b | 61.7 ± 4.2 a |
| IL-1β (pg/mL) | 20.2 ± 2.4 b | 48.6 ± 8.2 a | 49.4 ± 4.3 a | 32.3 ± 2.7 b | 24.1 ± 5.2 b | 43.4 ± 2.5 a |
| IL-6 (pg/mL) | 40.2 ± 1.9 ns | 41.8 ± 2.6 | 41.0 ± 2.1 | 39.4 ± 2.9 | 36.5 ± 2.8 | 38.2 ± 2.3 |
| Corticosterone (ng/mL) | 135 ± 14 b | 265 ± 27 a | 205 ± 19 a | 187 ± 11 a | 161 ± 13 b | 200 ± 16 a |
Fasting blood glucose (FBG), albumin (ALB), plasma triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (CRE), tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6) levels and plasma corticosterone levels. Values are presented as the mean ± SD (n = 6). ns = no significant difference. Different subscript letters indicated significant differences among groups at p < 0.05. N: control group; ND: D-galactose injection group; CD: CUMS + D-galactose injection group; PCD: CD + imipramine-treated group; FCD: CD + fish oil diet group; CCD: CD + corn oil diet group.
Figure 2Diversity analysis of microbiota compositions. (A) Shannon−Wiener diversity index; (B) Simpson’s diversity index; (C) Firmicutes/Bacteroidetes (F/B) ratio; (D) Heatmap of phylum abundance (E) Differences among groups were visualised through partial least squares discriminant analysis (n = 6). ns = no significant difference. Different superscript letters indicated significant differences among groups at p < 0.05.
Figure 3Linear discriminant analysis effect size analysis of microbiota compositions and network analysis of taxa. (A) Cladogram of microbiota compositions excluding the PCD group; (B) Heatmap of microbiota relative abundance; (C) Spearman’s correlation analysis of microbiota taxa, r cutoff = 0.7. Green lines indicate positive correlations. Red lines indicate negative correlations (n = 6).
Figure 4Bile acid profiles of rodent faecal samples. (A) Dominant primary bile acids in rodent faeces; (B) Dominant secondary bile acids in rodent faeces; (C) Levels of secondary bile acids 7−ketoLCA and DHLCA; (D) Levels of taurine-conjugated bile acids TUDCA and THDCA; (E) Heatmap of levels of 28 bile acids in each group. Data are expressed as means ± SDs (n = 6). Values with different superscript letters differ significantly (p < 0.05).
Figure 5Neurobehavioural outcomes and results of bile acid metabolite analysis. (A) Time spent immobile during forced swim test; (B) Time spent in platform zone during Morris water maze trial; (C) Secondary/primary bile acid ratio in each group; (D) Proportions of taurine-conjugated bile acids in faecal samples. Data are expressed as means ± SDs (n = 6). Values with different superscript letters differ significantly (p < 0.05).
Figure 6(A) The heatmap of Spearman’s correlation between the microbiota taxas and neurobehavioural test results. (B) The heatmap of Spearman’s correlation between the bile acids and neurobehavioural test results. Asterisk indicates significant differences between factors at p < 0.05.